Zobrazeno 1 - 10
of 95
pro vyhledávání: ''
Autor:
Max W. F. van Spengler, Laura H. Bukkems, Ron A. A. Mathôt, Tim Preijers, Marjon H. Cnossen, Frank W.G. Leebeek
Publikováno v:
European Journal of Clinical Pharmacology
European Journal of Clinical Pharmacology, 77(8), 1193-1200. Springer-Verlag
European journal of clinical pharmacology, 77(8), 1193-1200. Springer Verlag
European Journal of Clinical Pharmacology, 77(8), 1193-1200. Springer-Verlag
European journal of clinical pharmacology, 77(8), 1193-1200. Springer Verlag
Purpose Pharmacokinetic (PK) differences between the extended half-life (EHL) factor IX (FIX) concentrates for hemophilia B exist, which may influence hemostatic efficacy of replacement therapy in patients. Therefore, we aimed to evaluate the PK prop
Publikováno v:
European Journal of Clinical Pharmacology
Purpose Ivabradine has been approved for the treatment of chronic heart failure and chronic stable angina pectoris in Europe. Based on adverse outcomes of reproductive animal studies and the lack of human data, ivabradine is considered contraindicate
Autor:
Jonatan D. Lindh, Buster Mannheimer, Cecilia Fahlén Bergh, Henrik Falhammar, Jakob Skov, Jan Calissendorff
Publikováno v:
European Journal of Clinical Pharmacology
Purpose Thiazide diuretics are the most common origin of drug-induced hyponatremia. However, population-based studies on clinical outcomes are lacking. We therefore explored the time course and absolute risk of thiazide-associated hospitalization due
Publikováno v:
European Journal of Clinical Pharmacology, 77 (6)
European Journal of Clinical Pharmacology
European Journal of Clinical Pharmacology
Purpose In response to a large trial, the World Health Organization broadened their recommendation on tranexamic acid to be used for post-partum hemorrhage. A 2013 French periodic safety update report warned of an abnormally high rate of renal cortic
Autor:
Bernhard J. Connemann, Michael Denkinger, Emaad Abdel-Kahaar, Carlos Schönfeldt-Lecuona, Maximilian Gahr, Mohamed Elsayed
Publikováno v:
European Journal of Clinical Pharmacology
Purpose Most psychiatric drugs, such as antidepressants (AD) and antipsychotics (AP), may cause cardiac adverse events (CAE). We used summaries of product characteristics (SmPC) for assessing the likelihood of AD and AP to cause CAE. Methods We ident
Publikováno v:
European Journal of Clinical Pharmacology
Purpose To study the association between interacting drugs and bleeding or thromboembolism in atrial fibrillation outpatients treated with non-vitamin K antagonist oral anticoagulants (NOACs). Methods Population-based cohort study of outpatients trea
Publikováno v:
European Journal of Clinical Pharmacology
Purpose Drug-induced hyponatremia is common, with medications from many drug-classes implicated. Lipid-lowering agents are among the most prescribed drugs. Limited evidence suggests an inverse association between statins and hyponatremia, while data
Autor:
Khaldoun Ben Hamda, Mohsen Hassine, Sondess Hadj Fredj, Marwa Rezek, Taieb Messaoud, Linda Khefacha, Fadoua Neffeti, A. Sriha, Mayssa Gaaloul, Ilhem Hellara, Mouna Sassi, Faouzi Maatouk, Rym Dabboubi, Fatma Abderrazak, Saoussen Chouchene, Haythem Raddaoui, Mohamed Fadhel Najjar, H. Abroug, Semir Nouira
Publikováno v:
European Journal of Clinical Pharmacology. 74:1567-1574
Clopidogrel non-responsiveness is multifactorial; several genetic and non-genetic factors may contribute to impaired platelet inhibition. The goal of this study is to determine the effect of the cytochrome P450 CYP2C19*2 polymorphism on the platelet
Autor:
Letícia C. Tavares, Renata Alonso Gadi Soares, Nubia E. Duarte, Leiliane Rodrigues Marcatto, José Eduardo Krieger, Paulo Caleb Junior Lima Santos, Alexandre C. Pereira
Publikováno v:
European Journal of Clinical Pharmacology. 74:1555-1566
Interpatient variation of warfarin dose requirements may be explained by genetic variations and general and clinical factors. In this scenario, diverse population-calibrated dosing algorithms, which incorporate the main warfarin dosing influencers, h
Autor:
Markus Hinder, Thomas Langenickel, Gangadhar Sunkara, Uwe Schuehly, Georg Golor, Surya Ayalasomayajula, Margaret F. Prescott, Parasar Pal, Jeppe Buchbjerg
Publikováno v:
European Journal of Clinical Pharmacology. 74:1121-1130
Sacubitril/valsartan (LCZ696) and nitroglycerin share the second messenger cGMP and lower blood pressure. Given the potential for co-administration of both drugs in patients with heart failure, this study was designed to investigate the potential for